{
    "score": [
        1.0
    ],
    "extracted": [
        7
    ],
    "abstract": [
        "somewhat positive press coverage somewhat unlikely to affect edwards lifesciences share price ."
    ],
    "id": "823760.train",
    "article": [
        "news stories about edwards lifesciences have trended somewhat positive recently , according to accern sentiment analysis . accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time . accern ranks coverage of companies on a scale of negative one to positive one , with scores closest to one being the most favorable . edwards lifesciences earned a daily sentiment score of 0.18 on accern 's scale . accern also gave news headlines about the medical research company an impact score of 47.0961987469346 out of 100 , indicating that recent news coverage is somewhat unlikely to have an impact on the stock 's share price in the immediate future . ",
        "these are some of the headlines that may have effected accern sentiment analysis 's scoring : a number of equities analysts have recently issued reports on the stock . cowen set a $ 135.00 price objective on shares of edwards lifesciences and gave the company a `` buy '' rating in a research note on sunday , december 10th . bmo capital markets restated a `` buy '' rating and issued a $ 137.00 price objective on shares of edwards lifesciences in a research note on friday , december 8th . canaccord genuity restated a `` buy '' rating and issued a $ 137.00 price objective on shares of edwards lifesciences in a research note on wednesday , november 29th . ",
        "barclays upgraded shares of edwards lifesciences from an `` equal weight '' rating to an `` overweight '' rating and increased their price objective for the company from $ 125.00 to $ 135.00 in a research note on thursday , january 4th . finally , suntrust banks set a $ 124.00 price objective on shares of edwards lifesciences and gave the company a `` buy '' rating in a research note on wednesday , october 25th . six analysts have rated the stock with a hold rating , fifteen have issued a buy rating and one has given a strong buy rating to the stock . ",
        "edwards lifesciences presently has a consensus rating of `` buy '' and a consensus target price of $ 129.57 . edwards lifesciences traded down $ 1.01 on wednesday , hitting $ 118.50 . 766,781 shares of the stock traded hands , compared to its average volume of 1,560,000 . the company has a current ratio of 3.49 , a quick ratio of 2.76 and a debt-to-equity ratio of 0.33 . edwards lifesciences has a fifty-two week low of $ 86.55 and a fifty-two week high of $ 121.45 . the company has a market cap of $ 25,080.00 , a price-to-earnings ratio of 34.45 , a price-to-earnings-growth ratio of 1.86 and a beta of 0.51 . ",
        "edwards lifesciences last posted its earnings results on tuesday , october 24th . the medical research company reported $ 0.84 earnings per share for the quarter , missing the thomson reuters ' consensus estimate of $ 0.86 by . edwards lifesciences had a return on equity of 27.22 % and a net margin of 22.47 % . the firm had revenue of $ 821.50 million during the quarter , compared to the consensus estimate of $ 833.85 million . during the same period in the previous year , the company posted $ 0.68 eps . the firm 's revenue for the quarter was up 11.1 % compared to the same quarter last year . ",
        "sell-side analysts predict that edwards lifesciences will post 3.76 eps for the current fiscal year . edwards lifesciences announced that its board of directors has approved a share repurchase program on thursday , december 7th that authorizes the company to buyback $ 1.00 billion in outstanding shares . this buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases . shares buyback programs are often an indication that the company 's leadership believes its shares are undervalued . in other edwards lifesciences news , vp donald e. bobo , jr. . sold 5,300 shares of the stock in a transaction dated wednesday , november 29th . ",
        "the shares were sold at an average price of $ 116.45 , for a total transaction of $ 617,185.00 . the sale was disclosed in a document filed with the sec , which is accessible through this link . also , director schack wesley w. von sold 1,000 shares of the stock in a transaction dated thursday , november 9th . the stock was sold at an average price of $ 104.15 , for a total transaction of $ 104,150.00 . following the sale , the director now directly owns 2,622 shares in the company , valued at approximately $ 273,081.30 . ",
        "the disclosure for this sale can be found here . in the last three months , insiders have sold 210,480 shares of company stock worth $ 23,056,527 . insiders own 2.13 % of the company 's stock . illegal activity warning : `` somewhat positive press coverage somewhat unlikely to affect edwards lifesciences share price '' was published by watch list news and is the property of of watch list news . if you are reading this news story on another publication , it was illegally copied and republished in violation of united states & international copyright law . the legal version of this news story can be viewed at lifesciences company profileedwards lifesciences corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient 's diseased or defective heart valve . ",
        "the company is engaged in patient-focused innovations for structural heart disease and critical care monitoring . its segments include united states , europe , japan and rest of world .   "
    ]
}